Invited Speakers



Plenary Lecture

  • Plenary Lecture 1 Drug screening and
    oncology drug discovery
    Todd Golub Broad Institute and Dana-Farber Cancer Institute USA CV
  • Plenary Lecture 2 AI based precision medicine
    Fabrice Andre The Institute Gustave-Roussy France CV
  • Plenary Lecture 3 Mechanism-based biomarkers for PD-1 blockade in cancer therapy
    Suzanne L. Topalian Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy USA CV
  • Plenary Lecture 4 Exploiting the DNA damage response pathway in cancer therapy
    Alan Ashworth University of California San Francisco USA CV

SCIENTIFIC SYMPOSIUM

Scientific Symposium 1 Tissue-agnostic therapeutics
  • Dung T. Le Johns Hopkins
    University School of Medicine     USA CV
  • David S. Hong MD Anderson Cancer Center USA CV
  • Vivek Subbiah MD Anderson Cancer Center USA CV
  • Alexander Drilon Memorial Sloan
    Kettering Cancer Center     USA CV
Scientific Symposium 2 Proteomics & epigenomics – Updates, clinical application, clinical trial
  • Yu-Ju Chen Academia Sinica Taiwan CV
  • Jong-Bae Park National Cancer Center Graduate School of Cancer Science and Policy Korea CV
  • Daehee Hwang Seoul National University Korea CV
  • Duhee Bang Yonsei University Korea CV
Scientific Symposium 3 Up to date knowledge of GU cancer
  • Himisha Beltran Dana Farber Cancer Institute, Harvard Medical School USA CV
  • Woo Kyun Bae Chonnam National University
    Hwasun Hospital     Korea CV
  • Minsuk Kwon Ajou University Hospital Korea CV
  • Ignacio Duran Hospital Universitario Marques de Valdecilla-Idival Santander Spain CV
Scientific Symposium 4 Big data & AI: Cancer genome & diagnosis
  • Bin Chen Michigan State University USA CV
  • Peter Park Harvard Medical School USA CV
  • Chan-Young Ock Lunit Inc. Korea CV
  • Zlatko Trajanoski Medical University of Innsbruck Austria CV
Scientific Symposium 5 New horizons of clinical immuno-oncology in early-stage cancer
  • Dae Ho Lee Asan Medical Center Korea CV
  • Sun Min Lim Yonsei Cancer Center Korea CV
  • Stephane Champiat Institute Gustave Roussy France CV
  • Young Kwang Chae Northwestern University USA CV
Scientific Symposium 6 Clinical genomics
  • Atsushi Ohtsu National Cancer Center Hospital East Japan CV
  • Emile E Voest The Netherlands Cancer Institute The Netherlands CV
  • Sejoon Lee Seoul National University
    Bundang Hospital     Korea CV
  • Hongseok Yun Seoul National University Hospital Korea CV
Scientific Symposium 7 Diffuse large B-cell lymphoma
  • Margaret Shipp Harvard Medical School USA CV
  • Yoon Kyung Jeon Seoul National University Hospital Korea CV
  • Tae Min Kim Seoul National University Hospital Korea CV
  • Michael R. Bishop University of Chicago Medicine USA CV
Scientific Symposium 8 Esophageal squamous cell carcinoma
  • Chang Hyun Kang Seoul National University Hospital Korea CV
  • Sung Ho Moon National Cancer Center Korea CV
  • Jong-Mu Sun Samsung Medical Center Korea CV
  • Ken Kato National Cancer Center Hospital Japan CV
Scientific Symposium 9 Clinical development of radioligand therapy (RLT)
  • Hongyoon Choi Seoul National University Hospital Korea CV
  • Karim Fizazi Gustave Roussy France CV
  • Stephen Moran Novartis Switzerland CV

JOINT SYMPOSIUM

ASCO/KSMO Joint Symposium 1 Application of precision medicine in rare cancers: Approaching genetic landscape into rare cancers
  • Razelle Kurzrock Medical College of Wisconsin USA CV
  • Bhumsuk Keam Seoul National University Hospital Korea CV
  • Andrea Necchi Vita-Salute San Raffaele University Italy CV
KSSO/KSMO Joint Symposium 2 Current issue & critical tip in MDT trial
  • Joon Oh Park Samsung Medical Center Korea CV
  • Joon Seong Park Gangnam Severance Hospital Korea CV
  • Soo Yeun Park Kyungpook National University Hospital Korea CV
  • Sang Hee Cho Chonnam National University Hwasun Hospital Korea CV
JSMO/KSMO Joint Symposium 3 Pharmacogenomics of targeted therapy and IO in Korea and Japan
  • Hidetoshi Hayashi Kindai University Japan CV
  • Sook Ryun Park Asan Medical Center Korea CV
  • Eun Kyung Lee National Cancer Center Korea CV
  • Taroh Satoh Osaka University Hospital Japan CV
ASCO/KSMO Joint Symposium 4 Hereditary cancers: Diagnosis, management, and clinical trials
  • Matthew Yurgelun Dana-Farber Cancer Institute USA CV
  • Seock-Ah Im Seoul National University Hospital Korea CV
  • Kara N. Maxwell Corporal Michael Crescenz VA Medical Center USA CV
KOSRO/KSMO Joint Symposium 5 Advance in radiotherapy and clinical application
  • Steven J. Chmura University of Chicago USA CV
  • Eui Kyu Chie Seoul National University Hospital Korea CV
  • Tae Hyun Kim National Cancer Center Korea CV
  • Tatsuya Ohno Gumma University Japan CV
KCSG/KSMO Joint Symposium 6 New trends in clinical trials
  • Aaron R. Hansen Princess Alexandra Hospital, Metro South Health Australia CV
  • Juhee Cho Samsung Medical Center Korea CV
  • Aaron C. Tan National Cancer Centre Singapore Singapore CV
  • Heeyoung Kim Medidata Korea CV
KSP/KSMO Joint Symposium 7 Digital pathology & AI
  • Faisal Mahmood Harvard Medical School USA CV
  • Sun Woo Kim Deep Bio Inc. Korea CV
  • Kee-Taek Jang Samsung Medical Center Korea CV
  • Geert Litjens Radboud University Medical Center The Netherlands CV
ESMO/KSMO Joint Symposium 8 Recent progress of precision medicine using genomic landscape in cooperation with agnostic approach
  • Krisztian Homicsko Lausanne University Hospital Switzerland CV
  • David Planchard Gustave Roussy France CV
  • Jean-Yves Blay Léon Bérard Center France CV
  • Jee Hyun Kim Seoul National University
    Bundang Hospital     Korea CV
KSR/KSMO Joint Symposium 9 Machine learning tech in diagnostic radiology
  • Won Hwa Kim Kyungpook National University
    Chilgok Hospital     Korea CV
  • Ho Sung Kim Asan Medical Center Korea CV
  • Jaeseung Shin Samsung medical center Korea CV

Oncology Multi-Disciplinary Symposium

Oncology Multi-Disciplinary Symposium 1
KOR
Korean Session
How to interpret BRCAs and beyond BRCAs gene mutations and how to manage cancer patients with those mutations
  • Young-gon Kim Samsung Medical Center Korea CV
  • Kyung-Hun Lee Seoul National University Hospital Korea CV
  • Sook-hee Hong The Catholic University of Korea. Seoul St. Mary’s Hospital Korea CV
  • Kyoung Eun Lee Ewha Womans University Mokdong Hospital Korea CV
  • Sungyoung Lee Seoul National University Hospital Korea CV
Oncology Multi-Disciplinary Symposium 2
  • Ronan Kelly The Charles A. Sammons Cancer Center at Baylor University Medical Center USA CV
  • Young Soo Park Asan Medical Center Korea CV

Multidisciplinary Oncology Team Education Session

Multidisciplinary Oncology Team Education Session 1
KOR
Korean Session
Cancer associated complication management
  • Yun-Gyoo Lee Kangbuk Samsung Hospital Korea CV
  • Hee Jun Kim Chung Ang University Hospital Korea CV
  • Sung Hee Lim Soonchunhyang University
    Bucheon Hospital     Korea CV
  • Hye Yoon Park Seoul National University Hospital Korea CV
Multidisciplinary Oncology Team Education Session 2
KOR
Korean Session
ABCs of precision medicine (For beginners of precision medicine)
  • Sehhoon Park Samsung Medical Center Korea CV
  • Ji-Won Kim Seoul National University Bundang Hospital Korea CV
  • Hyung-Don Kim Asan Medical Center Korea CV
  • Yoon-La Choi Samsung Medical Center Korea CV
Multidisciplinary Oncology Team Education Session 3
KOR
Korean Session
Familial cancer- Diagnosis, education, care
  • Sang Ah Han Kyung Hee University Hospital at Gangdong Korea CV
  • Myong Cheol Lim National Cancer Center Korea CV
  • Jin Young Kim Keimyung University’ Korea Korea CV
  • Sun-Young Kong National Cancer Center Korea CV

SPECIAL SYMPOSIUM

Special Symposium 1 Incorporating nuclear medicine theranostic approaches for cancer management
  • David Tai Wai Meng Singapore NCC Singapore CV
  • Joo Hyun O Seoul St. Mary's Hospital Korea CV
  • Yong-il Kim Asan Medical Center Korea CV

Luncheon Symposium

Luncheon Symposium 1 Present and future insight for the management of unresectable colorectal cancer
  • Jwa Hoon Kim Korea University Anam Hospital Korea CV
  • Sun Young Kim Asan Medical Center Korea CV
Luncheon Symposium 2 Raise the awareness about expanded new indication (KEYNOTE-522) of high risk early TNBC for KEYTRUDA and deliver the value of KEYTRUDA in the treatment of TNBC patients suffering from cancer and emphasizing the importance of early treatment
  • Min Hwan Kim Yonsei Cancer Center Korea CV
Luncheon Symposium 3 Patient management in real practices after the reimbursement approval of KEYTURUDA in the 1st line mNSCLC treatment
  • Byoung Chul Cho Yonsei Cancer Center Korea CV
Luncheon Symposium 4 Overview of biosimilar development and introduction to Samfenet and Onbevzi, the MFDS approved biosimilars for oncology treatment
  • Hue Kwon Samsung Bioepis Korea CV
  • Donghoon Shin Samsung Bioepis Korea CV

Satellite Symposium

Satellite Symposium 1 New era of NSCLC EGFR mutation treatment_Updated overall survival analysis: 3G EGFR TKI Lazertinib
  • Ji-Youn Han National Cancer Center Korea CV
Satellite Symposium 2 Efficacy and safety of Gavreto for RET+ patients
  • Dae Ho Lee Asan Medical Center Korea CV
Satellite Symposium 3 What is the roles of Lonsurf (TAS-102) for the treatment of CRC/GC patients?
  • Ji Hyung Hong The Catholic University of Korea St. Mary's Hospital Korea CV
  • Hyung-Don Kim Asan Medical Center Korea CV
Satellite Symposium 4 Delving deeper into the 1st & 2nd line setting CDK4/6 inhibitor data (abemaciclib) for patients with HR+/HER2- metastatic breast cancer
  • Antonio Llombart Hospital Arnau Vilanova Spain CV
Satellite Symposium 5 Treatment strategy for uHCC patients: What can we expect from TKIs in uHCC treatment?
  • Masayuki Kurosaki Musashino Red Cross Hospital Japan CV
  • Jaekyung Cheon Cha Bundang Medical Center Korea CV
Satellite Symposium 6 Palbociclib as first in class CDK4/6 inhibitor : Milestones since 2015 FDA approval
  • Hee Kyung Ahn Gachon University Gil Medical Center Korea CV
Satellite Symposium 7 Integrating novel agents into the treatment paradigm for LA/mUC: Current and future perspective
  • Yoon Ji Choi Korea University Anam Hospital Korea CV
Satellite Symposium 8 Perspective change for first line treatment strategy in advance renal cell carcinoma
  • Inkeun Park Asan Medical Center Korea CV
Satellite Symposium 9 Looking beneath the surface of HR+HER2- aBC
  • Dejan Juric Massachusetts General Hospital USA CV
Satellite Symposium 10 Navigating the maze of cancer therapies with the answers in your hands
  • Keun-Wook Lee Seoul National University Bundang Hospital Korea CV
  • Han Sang Kim Yonsei Cancer Center Korea CV
Satellite Symposium 11 Antiemetic usage today: Risk-adapted approach
  • Hyewon Ryu Chungnam National University Hospital Korea CV
Satellite Symposium 12 The evolving treatment landscape with IO based combinations in 1L GC and 1L RCC treatment
  • JinWon Kim Seoul National University Bundang Hospital Korea CV
  • Ji Hyun Park Konkuk University Medical Center Korea CV
Satellite Symposium 13 Transforming treatment in urothelial cancer with first-line maintenance treatment with Bavencio (Avelumab)
  • In-Ho Kim Catholic University Seoul St.Mary Hospital Korea CV
Satellite Symposium 14 1L treatment for ALK+NSCLC: How do we decide?
  • Te-Chun Hsia China Medical University Hospital Taiwan CV
Satellite Symposium 15 Comprehensive approach for the management of EGFRm NSCLC patients
  • Min Hee Hong Yonsei Cancer Center Korea CV
Satellite Symposium 16 Enabling precision medicine with comprehensive genomic profiling
  • Damon Hostin Illumina USA CV
  • Yeul Hong Kim Korea University Anam Hospital Korea CV